News
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial
Quidel and Ortho Announce Expected Closing of Ortho Transaction
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics
AMN Healthcare Honored as Prime Supplier of the Year for Work with Minority-Owned Businesses
AMN Healthcare, the nation’s leader in healthcare total talent solutions, has been named Prime Supplier of the Year by the Western Regional Minority Supplier Development Council for prioritizing
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4)
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Transgene’s Combined General Meeting of May 25, 2022
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Bernstein 38th
LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Goldman
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in
Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.61 billion for the second quarter ended April 30, 2022, an increase of 5% compared to the second quarter of 2021 and up 7% on a core
Quotient Appoints Kimberly Anstett to its Board of Directors
Quotient Technology Inc. (NYSE: QUOT) (“Quotient” or the “Company”), the leading digital media and promotions technology company, today announced that it has appointed Kimberly Anstett to the
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective
DGAP-News: BB BIOTECH AG: Disruptive technologies are changing an entire industry
Evolva successfully placed shares from authorized capital, raising CHF 6.3 million
ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the H.C. Wainwright
Innoviva to Acquire Entasis Therapeutics
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on
ICON Named Business & Finance Company of the Year and One of Forbes’ Best Employers for Diversity
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today